Agilent Technologies Introduces Powerful Enhancements to Leading Life Science Software
New GeneSpring Platform Enables Faster Discovery of Complex Relationships Across Multi-omic Data
SANTA CLARA, Calif., Oct. 29, 2014
Agilent Technologies Inc. (NYSE: A) today introduced a newly optimized GeneSpring software package for researchers focused on genomics, proteomics, metabolomics, transcriptomics or any combination of life science disciplines.
"The GeneSpring enhancements enable end users to discover relationships in their data and get to conclusions faster," said Steve Fischer, market director for Agilent's Life Science Research Division.
The new software package includes:
GeneSpring GX and Mass Profiler Professional, which now allow users to examine the strength and direction of the relationship among samples or between genes, proteins and metabolites, using Correlation Analysis. A correlation coefficient is calculated and displayed in the form of a heat map. Users can also visualize sample attributes such as tumor size, experimental time points or diet. Changes in the measured omics data can be lined up with corresponding changes in the sample attributes for fast discovery of associations.
Pathway Architect, which now supports the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. KEGG is the premier pathway content source. Customers with KEGG licenses can search, score, save and share their results on their hard drive using Agilent's Pathway Architect. These capabilities are unique to Agilent software.
Agilent provides hardware, software, consumables and assistance for all omics applications. The company's software allows researchers to easily interrogate data across multiple disciplines to reveal relationships that could not be shown by other means.
Ricarda Fenske, a research officer at the Australian Research Council's Centre of Excellence in Plant Energy Biology at the University of Western Australia, offers a case in point:
"In our research we are interested in correlating metabolites with each other," Fenske said. "The Correlation Analysis feature in Mass Profiler Professional allows us to achieve that in a timely manner. It enables us to discover relationships between metabolites so we can draw conclusions about treatment effects on pathways quickly."
"Across all omics disciplines, researchers are creating larger and larger data sets with more entities-genes, proteins and metabolites-that put a greater strain on their data-processing resources," added Agilent's Fischer. "Agilent designed GeneSpring GX, Mass Profiler Professional and Pathway Architect to be cloud-deployed, which can give researchers access to additional processing power and enhance their ability to collaborate with distant colleagues."
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company's 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, information regarding the separation of Agilent's electronic measurement business; future revenues, earnings and profitability; the future demand for the company's products and services; and customer expectations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of our customers' businesses; unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing, and the risk that we are not able to realize the savings expected from integration and restructuring activities.
In addition, other risks that Agilent faces include those detailed in Agilent's filings with the Securities and Exchange Commission, including our latest Form 10-K and Form 10-Q. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement.
# # #
+1 408 553 7093